Compare Nuwellis Inc (NUWE) vs UBS Group AG Registered Ordinary Shares (UBS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuwellis Inc vs UBS Group AG Registered Ordinary Shares — how do they compare? Nuwellis Inc trades at $0.7 (market cap $2.20M), while UBS Group AG Registered Ordinary Shares trades at $47.97 (market cap $142.70B). The key difference: UBS Group AG Registered Ordinary Shares is far larger — about 64863.6× Nuwellis Inc's market cap, and UBS Group AG Registered Ordinary Shares pays a 2.34% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nuwellis Inc for 26 Days and UBS Group AG Registered Ordinary Shares for 0 Days on average.
| NUWE | UBS | |
|---|---|---|
Market Cap | $2.20M | $142.70B |
Volume | 121,544 | 2,096,090 |
Sector | Health | Financials |
52-Week High | $146.65 | $55.72 |
52-Week Low | $0.68 | $36.41 |
Typical Hold Time | 26 Days | 0 Days |
Enterprise Value | -$1.52M | $314.41B |
Dividend Yield | — | 2.34% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →About UBS Group AG Registered Ordinary Shares
UBS is a global financial services company focused on wealth management, investment banking, and asset management. It serves private, corporate, and institutional clients.
Read more on UBS →
